Previous Close | 55.70 |
Open | 53.30 |
Bid | 53.50 x N/A |
Ask | 58.50 x N/A |
Day's Range | 53.30 - 54.60 |
52 Week Range | 52.77 - 54.60 |
Volume | |
Avg. Volume | 0 |
Market Cap | 852.331M |
Beta (5Y Monthly) | 0.90 |
PE Ratio (TTM) | 34.06 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jul 03, 2023 |
1y Target Est | N/A |
Villers-lès-Nancy, 7 May 2024 - 6:00 p.m. (CET) PRESS RELEASE Q1 2024 revenue: €53.3 million Contributions from new acquisitions offset the base effect from the Ségur digital healthcare investment programme.The Divisions that sell equipment are heavily impacted by the economic context. 2024 outlook: after a phase of significant investment, the Group is targeting a return to growth beginning in H2. Q1 revenue (€m)2023 reported basis2024 reported basisChange / Reported basis- Ségur2024+Ségur2023-
Villers-lès-Nancy, 29 March 2024 - 6:00 p.m. (CET) PRESS RELEASE 2023 Annual Results Annual results impacted by the overperformance at the end of 2022 and early 2023 driven by solutions introduced under the Ségur programme as well as an unfavourable economic climate Revenue: €219.7m, +2.6% Net Profit: €48.9m, +0.4% Net Profit attributable to Group shareholders: €47.0m, +1.4% The Current Operating Margin remains at a high level (25.4%)Dividend proposal for FY 2023: €1.25 per share (+9.2%) In €m20
Villers-lès-Nancy, 6 February 2024 - 6:00 p.m. (CET) PRESS RELEASE 2023 revenue: €219.7m, +2.6% Equasens Group reported growth in annual revenue, despite an unfavourable comparison base from the Ségur French Digital Healthcare investment programme combined with difficult economic conditions, particularly in the pharmacy sector. Consolidated revenueIn €m20232022Change2023 / 2022Q156.349.414.0% (*)Q256.4 54.2 4.0%Q3 50.1 50.10.0%Q457.060.4-5.5%12 month YTD 219.7 (**)214.1 +2.6% (*) Strong growth i